Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can light therapy dry out a swollen retina?

NCT ID NCT04847869

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This pilot study tests whether shining near-infrared light on the eye can reduce macular edema—swelling in the central retina—caused by a retinal vein occlusion. Six participants with this condition will receive 12 light treatments over about five weeks. The main goal is to see if the treatment decreases retinal thickness at 12 weeks, with secondary checks on vision changes and the need for standard rescue injections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Near-infrared light delivered via the Ellex Integre NIR laser
What this could lead to
If effective, this could offer a non-invasive, drug-free option to reduce retinal swelling and improve vision in people with retinal vein occlusion.
What could go wrong
This is a very small pilot study with only 6 participants, so results may not apply broadly. The treatment may not reduce swelling, and there is a risk of no vision improvement or the need for rescue injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Jan 2021

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis macular edema secondary to branch or central vein occlusion (BRVO or CRVO) * CMT of \>300 µm and less than 550 µm; * Best corrected visual acuity of 6/6 to 6/24 (letters 87 - 53); * Intraocular pressure \< 25 mmHg; * Written informed consent has been obtained. Exclusion Criteria: * Loss of vision due to other causes (e.g. age-related macular degeneration, myopic macular degeneration, DME); * Known allergy to agents used in the study e.g. fluorescein; * Women who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using reliable means of contraception; * Only eye (vision in other eye \<6/60); * Study eye is an amblyopic eye; * Macular oedema due to other causes; * Significant diabetic retinopathy; * An ocular condition that would prevent visual acuity improvement despite resolution of oedema (such as foveal atrophy or substantial premacular fibrosis; * Previous treatment with any anti-VEGF therapy or investigational drugs in the study eye at any time prior to baseline. * Previous use of intraocular or periocular steroids in study eye at any time prior to baseline; * Cataract surgery within the last 3 months; * Retinal laser treatment within the last 6 months; * Media opacity including cataract that already precludes adequate macular photography or cataract that is likely to require surgery within 6 months; * Intercurrent severe disease such as septicaemia, any condition which would affect follow-up; * History of chronic renal failure requiring dialysis or renal transplant; * Blood pressure \>180/120; * Participant has a condition or is in a situation that in the investigator's opinion may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macula edema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Macular Research Group, Save Sight Institute, The University of Sydney

    Sydney, New South Wales, 2000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.